Access exclusive insights, data and interviews with Pα+: learn more and subscribe today.
You are currently viewing COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results  and Business Highlights

COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business Highlights






Highlights:

  • Phase 3 pivotal program underway – important updates announced
  • Phase 3 long term follow up defined
  • Cash position at 31 December 2022 of $143.2 million
  • Conference call today at 8:00am ET (1:00pm UK)

LONDON, Feb. 28, 2023 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter and year-end 2022 and gave an update on recent progress across its business.

Kabir Nath, Chief Executive Officer, said, “During this past quarter, we commenced our COMP360 phase 3 pivotal program in treatment-resistant depression, a significant milestone for our area of science as these are the first ever phase 3 trials of psilocybin. We have also announced important updates to this program that accelerate the placebo-controlled trial pivotal data read out and streamline the long-term follow up as an integrated component of the pivotal trials. We are confident that this phase 3 program should generate the evidence to support a regulatory filing and to support broad patient access through integration into healthcare systems.”

Business highlights
COMP360 psilocybin therapy in treatment-resistant depression (TRD):

  • Phase 3 program underway, program composed of two pivotal trials with an integrated long-term outcomes component
    • Pivotal trial 1 (COMP 005): single dose monotherapy, n=255, top line data expected summer 2024
      • Updates to 005 accelerate data read out
    • Pivotal trial 2 (COMP 006): fixed repeat dose monotherapy, n=568, top line data expected mid-2025
    • Long term outcome component includes a single 25 milligram retreatment option for all qualifying patients
  • Phase 2b trial published in The New England Journal of Medicine

Additional COMP360 development activities:

  • Phase 2 trials in anorexia nervosa and post-traumatic stress disorder (PTSD) ongoing
  • Investigator-initiated studies across numerous additional indications including:
    • Bipolar disorder type II: data presented at ACNP showing treatment was well tolerated with 12 of 14 patients in remission at three months following a single 25 milligram administration of COMP 360 psilocybin therapy, and no subject having manic or hypomanic symptoms or an increase in suicidal ideation
    • Anorexia nervosa: 6 of 10 participants in remission from Eating Disorder Psychopathology following a single 25 milligram administration of COMP 360, treatment was well tolerated and 9 of 10 participants endorsed the experience as meaningful and therapeutic; data presented at the Society of Biological Psychiatry annual meeting in April 2022.
    • Major depressive disorder in adults: data from the University of Zurich published in The Lancet in December. This randomized blinded study enrolled 52 patients, comparing a weight-based dose of COMP360 to true placebo, and demonstrated compelling efficacy results with no new safety signal.

Financial highlights

  • Net loss for the year ended 31 December 2022 was $91.5 million, or $2.16 loss per share (including non-cash share-based compensation expense of $13.1 million), compared with $71.7 million, or $1.79 loss per share, during the same period in 2021 (including non-cash share-based compensation expense of $8.6 million).
  • Net loss for the three months ended 31 December 2022 was $30.9 million, or $0.73 loss per share (including non-cash share-based compensation expense of $3.3 million), compared with $25.7 million, or $0.61 loss per share, during the same period in 2021 (including non-cash share-based compensation expense of $2.8 million).
  • Research and development (R&D) expenses were $65.1 million for the year ended 31 December 2022, compared with $44.0 million during the same period in 2021. Of this increase, $6.7 million relates to an increase in external development expenses as the Company continues to investigate COMP360 psilocybin therapy in clinical and pre-clinical trials. $6.1 million relates to an increase in personnel expenses, due to increased headcount. A further $5.4 million was attributable to increased other expenses primarily related to an increase in external consulting expenses. In addition, non-cash share-based compensation increased by $2.8 million, due to increased headcount.
  • R&D expenses were $19.8 million for the three months ended 31 December 2022, compared with $13.6 million during the same period in 2021. Of this increase, $2.7 million was attributable to an increase in other expenses, which primarily related to an increase in external consulting expenses. A further $2.3 million was attributable to an increase in external development expenses. Personnel expenses and non-cash share-based compensation increased by $1.0 million and $0.2 million respectively.
  • General and administrative (G&A) expenses were $45.4 million for the year ended 31 December 2022, compared with $39.2 million during the same period in 2021. The increase was attributable to an increase of $3.2 million in personnel expenses, due to increased headcount. A further $2.8 million and $1.7 million were attributable to legal and professional fees and non-cash share-based compensation respectively. The increases were offset by a decrease of $1.5 million in facilities and other expenses.
  • G&A expenses were $12.4 million for the three months ended 31 December 2022, compared with $14.7 million during the same period in 2021. The decrease was attributable to a decrease of $2.6 million and $1.0 million in facilities and other expenses and legal and professional fees respectively. This was partially offset by an increase of $1.0 million in personnel expenses and an increase of $0.3 million in non-cash share-based compensation expense, due to increased headcount.
  • Cash and cash equivalents were $143.2 million as of 31 December 2022, compared with $273.2 million as of 31 December 2021.

Financial Guidance

  • First quarter 2023 net cash used in operating activities is expected to be in the range of $24 million to $32 million and the full-year 2023 to be in the range of $85 million to $110 million.

Conference call
The COMPASS Pathways management team will host a conference call at 8.00am ET (1:00pm UK) on February 28, 2023. Please register in advance here to access the call and obtain a local or toll-free phone number and personal pin.
A live webcast of the call will be available on COMPASS Pathway’s website at: Fourth Quarter and Year End 2022 Financial Results. The webcast will also be available on the Investors section of the COMPASS Pathways website. The webcast will be archived for 30 days. The call will also be webcast on the COMPASS Pathways website and archived for 30 days. For more information, please visit the COMPASS Pathways website (ir.compasspathways.com).

About COMPASS Pathways
COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the U.S. Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD). We have commenced a phase 3 clinical program of COMP 360 psilocybin therapy in TRD, the largest randomised, controlled, double-blind psilocybin therapy clinical program ever conducted. Previously, we completed a phase 2b study with top line data showing a statistically significant (p<0.001) and clinically relevant improvement in depressive symptom severity after three weeks for patients who received a single high dose of COMP360 psilocybin with psychological support. We are also conducting phase 2 clinical studies of COMP360 psilocybin therapy for post-traumatic stress disorder (PTSD) and anorexia nervosa. COMPASS is headquartered in London, UK, with offices in New York and San Francisco in the United States. Our vision is a world of mental wellbeing. www.compasspathways.com

Availability of other information about COMPASS Pathways
Investors and others should note that we communicate with our investors and the public using our website (www.compasspathways.com), our investor relations website (ir.compasspathways.com), and on social media (LinkedIn), including but not limited to investor presentations and investor fact sheets, US Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, forward-looking statements can be identified by terminology such as “may”, “might”, “will”, “could”, “would”, “should”, “expect”, “intend”, “plan”, “objective”, “anticipate”, “believe”, “contemplate”, “estimate”, “predict”, “potential”, “continue” and “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things, COMPASS’s business strategy and goals, our expectations and projections about the company’s future financial results, the Company’s plans and expected timing for its phase 3 program in TRD and the potential for that or other trials to support regulatory filings and approvals, the Company’s expectations regarding amendments to its phase 3 protocols and results of ongoing discussions with FDA, the safety or efficacy of its investigational COMP360 psilocybin therapy, including for treatment of TRD, anorexia nervosa, PTSD, bipolar type II and major depressive disorder, and COMPASS’s expectations regarding its ongoing preclinical work and clinical trials, development efforts and innovation labs. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond COMPASS’s control and which could cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forward-looking statements.

These risks, uncertainties, and other factors include, among others: clinical development is lengthy and outcomes are uncertain, and therefore our clinical trials may be delayed or terminated,; our efforts to obtain marketing approval from the applicable regulatory authorities in any jurisdiction for COMP360 or any of future product candidates may be unsuccessful; our development efforts and our business strategy to set up research facilities and innovation labs will involve significant costs and resources and may be unsuccessful; and those risks and uncertainties described under the heading “Risk Factors” in COMPASS’s most recent annual report on Form 10-K or quarterly report on Form 10-Q and in other reports we have filed with the U.S. Securities and Exchange Commission (“SEC”) , which are available on the SEC’s website at www.sec.gov. Except as required by law, COMPASS disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on COMPASS’s current expectations and speak only as of the date hereof.

Enquiries
Media: Amy Lawrence, amy@compasspathways.com, +44 7813 777 919
Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290 7324

COMPASS PATHWAYS PLC
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
(expressed in U.S. Dollars, unless otherwise stated)

  December 31,
  2022   2021
ASSETS      
CURRENT ASSETS:      
Cash and cash equivalents $        143,206           $        273,243        
Restricted cash         175                   104        
Prepaid income tax         575                   332        
Prepaid expenses and other current assets         47,695                   21,621        
Total current assets         191,651                   295,300        
NON-CURRENT ASSETS:      
Investment         469                   525        
Property and equipment, net         617                   398        
Operating lease right-of-use assets         2,006                   3,696        
Deferred tax assets         2,224                   766        
Other assets         327                   213        
Total assets $        197,294           $        300,898        
LIABILITIES AND SHAREHOLDERS’ EQUITY      
CURRENT LIABILITIES:      
Accounts payable $            4,761           $            2,564        
Accrued expenses and other liabilities         9,325                   10,308        
Operating lease liabilities – current         1,510                   2,235        
Total current liabilities         15,596                   15,107        
NON-CURRENT LIABILITIES      
Operating lease liabilities – non-current         418                   1,379        
Total liabilities         16,014                   16,486        
       
Commitments and contingencies (Note 15)      
SHAREHOLDERS’ EQUITY:      
Ordinary shares, £0.008 par value; 42,631,794 and 42,019,874 shares authorized, issued and outstanding at December 31, 2022 and 2021, respectively         440                   435        
Deferred shares, £21,921.504 par value; one share authorized, issued and outstanding at December 31, 2022 and 2021         28                   28        
Additional paid-in capital         458,825                   444,750        
Accumulated other comprehensive (loss)/income         (16,867)                   8,840        
Accumulated deficit         (261,146)                   (169,641)       
Total shareholders’ equity         181,280                   284,412        
Total liabilities and shareholders’ equity $        197,294           $        300,898        
       

COMPASS PATHWAYS PLC
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
(expressed in U.S. Dollars, unless otherwise stated)

  Three Months Ended December 31,   Twelve Months Ended December 31,
  2022   2021   2022   2021
OPERATING EXPENSES:              
Research and development $19,794   $13,593   $65,053   $44,027
General and administrative 12,397   14,730   45,350   39,194
Total operating expenses 32,171   28,323   110,403   83,221
LOSS FROM OPERATIONS: (32,191)   (28,323)   (110,403)   (83,221)
OTHER INCOME (EXPENSE), NET:              
Other income, net 481   38   4,061   40
Foreign exchange gains (losses) (3,566)   (181)   821   1,990
Benefit from R&D tax credit 4,442   2,915   14,424   9,648
Total other income (expense), net 1,357   2,772   19,306   11,678
Loss before income taxes (30,834)   (25,551)   (91,097)   (71,543)
Income tax expense (92)   (99)   (408)   (199)
Net loss (30,926)   (25,650)   (91,505)   (71,742)
Other comprehensive loss:              
Foreign exchange translation adjustment 13,776   1,076   (25,707)   (5,745)
Comprehensive loss (17,150)   (24,574)   (117,212)   (77,487)
Net loss per share attributable to ordinary shareholders—basic and diluted $(0.73)   $(0.61)   $(2.16)   $(1.79)
Weighted average ordinary shares outstanding—basic and diluted 42,436,292   39,997,587   42,436,292   39,997,587
               

Source link

Leave a Reply

Join Our Newsletter

Subscribe to Pα+

Consider subscribing Pα+ for exclusive insights, interviews and analysis.